Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Astra And Moderna Vaccine News Push Stocks Up

Wed, 15th Jul 2020 17:16

(Alliance News) - Stocks in London ended Wednesday firmly in the green as sentiment was boosted from positive news from test trials of potential Covid-19 vaccines.

The FTSE 100 index added 112.90 points, or 1.8%, to 6,292.65. The mid-cap FTSE 250 index closed up 245.86 points, or 1.4%, at 17,420.55. The AIM All-Share index ended up 8.92 points, or 1.0% at 875.47.

The Cboe UK 100 index closed up 2.1% at 628.11. The Cboe 250 added 1.6% to 14,767.44, and the Cboe Small Companies closed up 0.2% at 9,172.68.

In mainland Europe, the CAC 40 in Paris advanced 2.0%, while the DAX 30 in Frankfurt added 1.8%.

Oanda Edward Moya commented: "Global stocks continue to rally on encouraging incremental vaccine news. Hope is sky high that a vaccine will be in place by the end of the year and that is driving the reopening trade again."

"Stocks are riding both Moderna's human trial data news and press reports that AstraZeneca will have positive news with their vaccine by tomorrow," Moya continued.

Hopes rose when US biotech firm Moderna said late Tuesday that it will start the final stage of human trials for its vaccine candidate later this month after promising results from earlier testing. The vaccine produced antibodies in all 45 patients who received two injections 28 days apart in March, said the study published in the New England Journal of Medicine.

Adding to this, positive news on initial trials of the University of Oxford's potential Covid-19 vaccine that has been licensed to AstraZeneca could be announced as soon as Thursday, according to ITV.

The project has started Phase III of the human trials to assess how the vaccine works in a large number of people over the age of 18, but has yet to report Phase I trial results.

"I am hearing there will be positive news soon (perhaps tomorrow) on initial trials of the Oxford Covid-19 vaccine that is backed by AstraZeneca," ITV's Robert Peston said in a blog post on Wednesday.

Astra advanced 5.2% in London on Wednesday. Travel stocks reacted positively to the news too, with Carnival and International Consolidated Airlines both gaining 11% and easyJet adding 6.4%.

The DJIA was up 0.9% at the London equities close, the S&P 500 index up 0.8%, and the Nasdaq Composite was up 0.4%.

"Global equities are acting like a vaccine put is in place. Vaccine progress is helping traders look beyond all the negative coronavirus and US-Chinese tensions headlines. A vaccine put is essentially in place until we get the critical phase 3 updates which haven't even started yet," Oanda's Moya said.

Back in London, Ocado added 6.6%, regaining the 2.2% loss from Tuesday. The online grocer, on Tuesday, said it delivered a strong performance considering the challenging times created by the Covid-19 pandemic.

For the half-year ended May 31, Ocado's pretax loss narrowed to GBP40.6 million from GBP147.4 million a year before, as revenue increased to GBP1.09 billion from GBP882.3 million. Ocado said the coronavirus crisis has significantly accelerated the ongoing shift by consumers to online grocery.

Looking ahead, Ocado said there is a positive outlook for online grocery, but it has suspended its Retail revenue growth forecast given uncertainties over the scale and duration of social distancing restrictions in the UK.

3i Group added 5.2% after Exane BNP started coverage on the private equity investor with an Outperform rating.

At the other end of the blue chip index, Burberry lost 5.6% - the worst performer - after the fashion house said sales in the first quarter took a severe hit, as demand for luxury goods was dealt a blow due to the coronavirus pandemic.

For the period ending June 27, retail revenue was down 48% to GBP257 million from GBP498 million in the first quarter of 2019. Comparable sales declined 45% in the first quarter, but eased to a 20% decline in the month of June as lockdown restrictions became less stringent.

The luxury retailer expects the second quarter to end of September to continue to suffer from the pandemic. In retail, it said, tourist flows are likely to remain negligible, and store operations are continuing to face significant pressures, with some remaining closed and operating with reduced trading hours.

Burberry expects retail sales performance to decline by 15% to 20% in the second quarter. In wholesale, it is collaborating with partners to protect the brand and as a result, anticipates first-half sales to fall around 40% to 50%.

It added that it expects its first-half gross margin to decline by between 200 and 300 basis points annually, but operating expenses to be cut by "mid-teens percentage".

BT Group gave back 1.9% but UBS reiterated its Neutral rating for the firm saying the UK government's decision to ban Huawei from the country's 5G networks removes an overhang weighing on the telecom stock.

BT said Tuesday the UK government's move to remove Chinese tech giant Huawei from the country's 5G network will cost about GBP500 million.

The UK on Tuesday bowed to growing US pressure and ordered the phased removal of Chinese telecoms giant Huawei from its 5G network despite warnings of retaliation from Beijing. The policy reversal hands a long-sought victory to US President Donald Trump's administration in its geopolitical tug-of-war with China.

The politically-fraught change in Britain's digital future was made by UK Prime Minister Boris Johnson during a meeting with his cabinet and National Security Council. It requires companies to stop buying new 5G equipment from Huawei starting next year and strip out existing gear by the end of 2027.

UBS analyst Polo Tang said that while a Huawei swap-out will lead to incremental capital expenditure, the impact is largely captured in existing estimates for most of the UK operators and there has already been significant news flow on the issue in recent weeks. Further, the analyst thinks clarity on the issue removes an "overhang for the UK names, particularly for BT".

In the midcaps, Hochschild Mining added 13%. The gold miner said that second-quarter and first-half production was impacted by the Covid-19 pandemic, but the company expects to restart operations at the Inmaculada mine in Peru by next week.

Hochschild, which also operates mines in Argentina, said attributable gold production in the six months to June 30 fell to 79,073 ounces from 138,080 ounces a year ago. Silver production fell to 4.1 million ounces from 8.7 million ounces.

For the second quarter, attributable gold production declined to 19,647 ounces from 70,660 ounces. Silver output fell to 1.1 million ounces from 2.9 million.

Hochschild Mining said its operations are currently halted due to a number of cases of Covid-19 with a reduced workforce performing care and maintenance activities. The Inmaculada mining team is expected to remobilise during the week starting July 20 and is scheduled to reach full production by the end of July.

Sitting at the bottom of the FTSE 250, electrical retailer Dixons Carphone lost 9.4%. Dixons decided against issuing guidance for financial 2021 due to the "high levels of uncertainty" created by the Covid-19 pandemic, but warned that its mobile phones business will be hurt by the virus outbreak.

Dixons Carphone reported a narrowed pretax loss for the financial year that ended May 2 of GBP140 million compared with a GBP259 million loss a year ago.

Adjusted pretax profit fell 51% to GBP166 million from GBP339 million due to a poor performance from its mobile phones business and Covid-19 related store closures.

The adjusted profit figure was GBP44 million below the company's guidance reiterated in January.

The pound was quoted at USD1.2604 at the London equities close Wednesday, up from USD1.2547 at the same time Tuesday.

The euro was changing hands at USD1.1419, up from USD1.1403 at the European equities close Tuesday. The single currency hit an intraday high of USD1.1444 against the greenback in early trade - its highest level in four months.

Against the yen, the dollar was trading at JPY106.88, down from JPY107.21 in London.

Brent oil was trading at USD43.42 a barrel Wednesday evening, up from USD43.10 at the London close Tuesday.

Oanda's Moya commented: "Crude prices jumped around following both the OPEC+ recommendation to slowly bring back some oil supplies and after the EIA crude oil inventory reported showed a much larger draw and some signs demand is improving."

Gold was quoted at USD1,809.00 an ounce, flat against USD1,808.60 late Tuesday.

Thursday's economics calendar is headlines by the European Central Bank rate decision at 1245 BST. Before that, there is second quarter China GDP print overnight and a UK ILO unemployment rate at 0700 BST. There is also a eurozone trade balance print at 1000 BST. Weekly US initial jobless claims are scheduled for a 1330 BST release.

In the UK corporate events calendar, mining giant Anglo American will issue half-year production figures, consumer credit reporter Experian will issue its first quarter results and recruiter Hays is scheduled to issue a trading statement.

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more
19 Feb 2024 08:44

LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest

(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.